Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469666 | 0.92 | RAB9A (0.34) | RAB9AKDM4ESMN1; SMN2NPC1MAPK1 | |
| SCHEMBL15469664 | 0.91 | RAB9A (0.32) | RAB9AKDM4ESMN1; SMN2NPC1MAPK1 | |
| SCHEMBL15469672 | 0.89 | KMT2A (0.34) | RAB9ANPC1ALDH1A1F2GLA | |
| SCHEMBL15469642 | 0.88 | KDM4E (0.31) | RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL15469671 | 0.86 | ALDH1A1 (0.30) | ALDH1A1F2GLAHPGD | |
| SCHEMBL15469661 | 0.82 | RAB9A (0.34) | RAB9AKDM4ESMN1; SMN2NPC1MAPK1 | |
| SCHEMBL1926439 | 0.81 | HPGDS (0.38) | RAB9AKDM4ESMN1; SMN2NPC1MAPK1 | |
| SCHEMBL15469610 | 0.80 | RAB9A (0.33) | RAB9AKDM4ESMN1; SMN2NPC1MAPK1 | |
| SCHEMBL15469674 | 0.79 | ALDH1A1 (0.31) | ALDH1A1F2GLAHPGD | |
| SCHEMBL15469622 | 0.79 | KMT2A (0.34) | RAB9ANPC1ALDH1A1F2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045890-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045890-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045890-A1 | NOVEL COMPOUNDS | CYP1B1, CYP1A1, CYP51A1 | RAB9A 1433/4885KDM4E 747/4885SMN1; SMN2 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.